David Gilligan, MD
Clinical Cardiac Electrophysiology · Richmond, VANPI 1184641045
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $12,000 of the $14,300 with a category attached, or 83.9%. Biotronik NRO, Inc. accounts for 83.9% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2024 at $12,387 and has fallen 96.3% since, to $464 in 2025. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in VA, where the typical reported total is $19,771.
Across 73 payments — averaging $195.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotronik NRO, Inc.$12K
- Abbott$561
- Boston Scientific$346
- Medtronic$281
- E.r. Squibb & Sons, L.L.C.$235
- Impulse Dynamics (USA) Inc.$197
- plus $681 from 18 others
Across 39 payments — averaging $2350.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$79K
- Atricure, Inc.$9K
- Abbott$4K
What the payments were for
- Speaking & faculty fees$12,00084%
- Food & beverage$2,30016%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotronik NRO, Inc. | 2 | $12,000 |
| Abbott | 5 | $561 |
| Boston Scientific | 10 | $346 |
| Medtronic | 4 | $281 |
| E.r. Squibb & Sons, L.L.C. | 8 | $235 |
| Impulse Dynamics (USA) Inc. | 6 | $197 |
| Novartis | 9 | $171 |
| Pfizer | 4 | $68 |
| Amgen | 4 | $61 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $51 |
| Cardiva Medical, Inc. | 2 | $40 |
| Johnson & Johnson | 2 | $36 |
| Boehringer Ingelheim | 2 | $36 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $33 |
| Atricure, Inc. | 2 | $28 |
| Angiodynamics, Inc. | 1 | $22 |
| Bardy Diagnostics, Inc. | 1 | $20 |
| Bridgebio Pharma, Inc. | 1 | $20 |
| Kestra Medical Technology Services, Inc. | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Bard Access Systems, Inc. | 1 | $15 |
| Merck | 1 | $14 |
| Itamar Medical Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prospera$12,000
- Perclose ProStyle$288
- Micra$178
- AMPLATZER Occluders$129
- CAMZYOS$124
- PERCLOSE PROGLIDE$123
- OPTIMIZER$114
How this compares
$14,300 in reported general payments places this provider in the 40th percentile of 90 clinical cardiac electrophysiology providers in Virginia.
See all clinical cardiac electrophysiology providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 337 | $373,019 |
| XareltoRivaroxaban | 131 | $157,927 |
| EntrestoSacubitril/Valsartan | 29 | $37,409 |
| Dofetilide | 48 | $17,776 |
| Flecainide Acetate | 219 | $7,257 |
| Metoprolol Succinate | 271 | $3,661 |
| Amiodarone Hcl | 149 | $2,633 |
| SotalolSotalol Hcl | 92 | $1,557 |
| Carvedilol | 175 | $1,302 |
| Spironolactone | 189 | $1,196 |
| Losartan Potassium | 110 | $931 |
| Bumetanide | 21 | $549 |
| Lisinopril | 93 | $543 |
| Dilt-XrDiltiazem Hcl | 13 | $529 |
| Amlodipine Besylate | 113 | $525 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $68 | $373,019337 claims |
| Johnson & JohnsonXarelto | $36 | $157,927131 claims |
| NovartisEntresto | $171 | $37,40929 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 90 clinical cardiac electrophysiology providers in Virginia.
Other clinical cardiac electrophysiology in Richmond
- Kenneth EllenbogenRichmond$360K
- Ajay PillaiRichmond$129K
- Charles JoynerRichmond$85K
- Binaya BasyalRichmond$79K
- Jayanthi KoneruRichmond$62K
- Kyaw Min KhantRichmond$51K
- Jacob BlackwellRichmond$49K
- Pranav MankadRichmond$30K
- Vybhav JettyRichmond$20K
- Harsimran SainiRichmond$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.